SCHEMBL19585563

SCHEMBL19585563

CC(C)(C)OC(=O)N1CCC(O)(c2cccc3c2CN(C2CCC(=O)NC2=O)C3=O)CC1

nearest known ligand 0.55

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ CRBN Q96SW2 13/20 0.55
▸ IKZF3 Q9UKT9 6/20 0.52
▸ DDB1 Q16531 4/20 0.52
▸ IKZF1 Q13422 2/20 0.52
▸ BRD4 O60885 1/20 0.52
▸ TNF P01375 1/20 0.52
▸ IL1B P01584 1/20 0.52
▸ MAP1LC3B Q9GZQ8 7/20 0.46
▸ CSNK1A1 P48729 1/20 0.46
▸ GSPT1 P15170 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19585580 0.91 CRBN (0.54) CRBNIKZF3DDB1IKZF1BRD4
SCHEMBL31736534 0.88 CRBN (0.46) CRBNIKZF3DDB1IKZF1BRD4
SCHEMBL31753300 0.85 CRBN (0.54) CRBNIKZF3DDB1IKZF1BRD4
SCHEMBL27099085 0.85 CRBN (0.58) CRBNIKZF3DDB1IKZF1BRD4
SCHEMBL30135733 0.85 CRBN (0.58) CRBNIKZF3DDB1IKZF1BRD4
SCHEMBL19606271 0.84 CRBN (0.64) CRBNIKZF3DDB1IKZF1BRD4
SCHEMBL19585928 0.84 CRBN (0.57) CRBNIKZF3DDB1IKZF1BRD4
SCHEMBL31072968 0.83 CRBN (0.54) CRBNDDB1MAP1LC3BGSPT1
SCHEMBL24816859 0.83 CRBN (0.55) CRBNIKZF3DDB1IKZF1BRD4
SCHEMBL31747465 0.83 CRBN (0.55) CRBNIKZF3DDB1IKZF1BRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250127903-A1 SUBSTITUTED PIPERIDINE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION C4 THERAPEUTICS, INC. (US) 2025-04-24 — — US disclosed
US-12048747-B2 Substituted piperidine Degronimers for Target Protein degradation C4 THERAPEUTICS, INC. (US) 2024-07-30 — — US disclosed
US-20220313827-A1 SUBSTITUTED PIPERIDINE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION C4 THERAPEUTICS, INC. (US) 2022-10-06 — — US disclosed
EP-3455219-A1 AMINE-LINKED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION C4 Therapeutics, Inc. (US) 2019-03-20 — — EP disclosed
US-20190076539-A1 AMINE-LINKED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION C4 Theraprutics, Inc. (US) 2019-03-14 — — US disclosed
US-20190076539-A1 AMINE-LINKED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION C4 Theraprutics, Inc. (US) 2019-03-14 — — US disclosed
WO-2017197056-A1 BROMODOMAIN TARGETING DEGRONIMERS FOR TARGET PROTEIN DEGRADATION C4 THERAPEUTICS, INC. (US) 2017-11-16 — — WO disclosed
WO-2017197051-A1 AMINE-LINKED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION C4 THERAPEUTICS, INC. (US) 2017-11-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250127903-A1 SUBSTITUTED PIPERIDINE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION STUB1, UBE3C, NEDD4 CRBN 77/4885IKZF3 2159/4885DDB1 769/4885
US-20190076539-A1 AMINE-LINKED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION GCGR, STUB1, GID4 CRBN 23/4885IKZF3 3499/4885DDB1 503/4885
US-20220313827-A1 SUBSTITUTED PIPERIDINE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION STUB1, UBE3C, NEDD4 CRBN 77/4885IKZF3 2159/4885DDB1 769/4885
US-12048747-B2 Substituted piperidine Degronimers for Target Protein degradation GID4, RNF5, UBE3C CRBN 105/4885IKZF3 2272/4885DDB1 716/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback